| Literature DB >> 32228522 |
Caroline King1,2, Le Minh Giang3, Gavin Bart4, Lynn Kunkel5, P Todd Korthuis5,6.
Abstract
BACKGROUND: Little is known about patient characteristics that contribute to initiating antiretroviral therapy (ART) and achieving viral suppression among HIV people with opioid use disorder in Vietnam. The primary objective of this analysis was to evaluate associations between participant characteristics and the critical steps in the HIV care continuum of ART initiation and HIV viral suppression among people with opioid use disorder and HIV in Vietnam.Entities:
Keywords: Anti-retroviral medication; HIV care continuum; HIV viral suppression; Opioid use; Vietnam
Mesh:
Substances:
Year: 2020 PMID: 32228522 PMCID: PMC7106608 DOI: 10.1186/s12889-020-08538-3
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 4.135
Unadjusted and adjusted associations between baseline characteristics and ART prescription and viral suppression among people with HIV and opioid use disorder in Vietnam, 2015–2019
| All participants | Prescribed ART | Virally suppressed | |||
|---|---|---|---|---|---|
| n (%) | Unadjusted | Adjusted | Unadjusted | Adjusted | |
| 38.3 (6.1) | 38.8 (6.0) | 1.02 (0.97, 1.07) | 38.8 (6.0) | 1.04 (0.98, 1.10) | |
| 274 (96.8%) | – | – | – | ||
| – | – | ||||
| Yes | 115 (40.6%) | 77 (40.3%) | 76 (40.2%) | ||
| No | 168 (59.4%) | 114 (59.7%) | 113 (60.0%) | ||
| – | – | ||||
| Yes | 130 (45.9%) | 92 (48.2%) | 93 (49.2%) | ||
| No | 153 (54.1%) | 99 (51.8%) | 96 (50.8%) | ||
| 2.83 (1.51, 5.34) | 1.44 (0.69, 3.03) | ||||
| Yes | 109 (38.5%) | 85 (44.5%) | 84 (44.4%) | ||
| No | 174 (61.5%) | 106 (55.5%) | 105 (55.6%) | ||
| – | – | – | – | ||
| Yes | 234 (82.7%) | ||||
| No | 46 (16.3%) | ||||
| 2.2 (1.7) | – | – | |||
| 1.58 (0.88, 2.85) | 1.14 (0.55, 2.34) | ||||
| Yes | 172 (60.8%) | 125 (65.4%) | 112 (59.3%) | ||
| No | 111 (39.2%) | 66 (34.6%) | 67 (35.4%) | ||
| – | – | 25.4 (12.13, | |||
| Yes | 191 (67.5%) | 168 (88.9%) | 53.11) | ||
| No | 92 (32.5%) | 17 (9.0%) | |||
| 7.4 (5.7) | 8.4 (5.4) | 1.12 (1.06, 1.19) | 0.99 (0.93, 1.06) | ||
| 405.0 (224.1) | – | – | |||
| – | – | ||||
| Yes | 232 (82.0%) | 154 (80.6%) | 153 (81.0%) | ||
| No | 51 (18.0%) | 37 (19.4%) | 36 (19.0%) | ||
| – | – | ||||
| Yes | 90 (31.8%) | 56 (29.3%) | 53 (28.0%) | ||
| No | 193 (68.2%) | 126 (66.0%) | 130 (68.8%) | ||
| 0.55 (0.28, 1.09) | 0.74 (0.32, 1.70) | ||||
| Yes | 53 (18.7%) | 31 (16.2%) | 30 (15.9%) | ||
| No | 230 (81.3%) | 160 (83.8%) | 159 (84.1%) | ||
| – | – | ||||
| Yes | 4 (1.4%) | ||||
| No | 279 (98.6%) | ||||
| – | – | ||||
| Yes | 1 (0.4%) | ||||
| No | 282 (99.6%) | ||||
| 4.5 (8.3) | 4.42 (9.8) | – | 4.48 (9.8) | – | |
| 5.4 (12.1) | 5.7 (14.4) | – | 5.7 (14.5) | – | |
| 6.1 (10.2) | 5.1 (7.3) | 0.97 (0.94, 0.9963) | 5.3 (7.4) | 0.99 (0.96, 1.03) | |
aIncludes methamphetamines and amphetamines
Fig. 1HIV care continuum among people with co-occurring opioid use disorder, 2015 to 2019